The role of the acute phase response in Docetaxel resistance in hormone-refractory prostate cancer.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1018149

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Prostate cancer is the most common cancer in Australian men. Chemotherapy is used in advanced disease, but is only effective in ~50% of patients. In the first year of my PhD, I identified 8 plasma biomarkers that predict chemotherapy resistance. I plan to characterise how these immune molecules cause chemotherapy resistance using a mouse model of advanced prostate cancer. These markers may allow us to personalise prostate cancer treatment in the future and identify more effective therapies.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2012

Funding Scheme: NHMRC Postgraduate Scholarships

Funding Amount: $74,365.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Chemotherapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

chemotherapy | chemotherapy treatment effects | cytokines | hormone-refractory prostate cancer | individualising management | inflammation | prognostic markers | prostate cancer

Related Links